Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GALT 
Galectin Therapeutics Inc (GALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.96% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 237.98M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.83 | 52 Weeks Range 0.73 - 4.41 | Updated Date 08/14/2025 |
52 Weeks Range 0.73 - 4.41 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
Earnings Date
Report Date 2025-08-18 | When - | Estimate -0.19 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -143.58% | Return on Equity (TTM) -3727.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 335059116 | Price to Sales(TTM) - |
Enterprise Value 335059116 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.04 | Shares Outstanding 63291600 | Shares Floating 44156640 |
Shares Outstanding 63291600 | Shares Floating 44156640 | ||
Percent Insiders 30.45 | Percent Institutions 14.17 |
Upturn AI SWOT
Galectin Therapeutics Inc
Company Overview
History and Background
Galectin Therapeutics Inc. was founded in 2000. It is a biotechnology company focused on developing therapies for fibrotic diseases and cancer.
Core Business Areas
- Therapeutics Development: Developing galectin inhibitors for the treatment of NASH cirrhosis and other fibrotic diseases. Primary focus on Galectin-3 inhibition.
Leadership and Structure
Dr. Joel Lewis is the Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Belapectin: An investigational drug being developed for the treatment of NASH cirrhosis and potentially other fibrotic diseases. Currently in clinical trials. There is no market share as it is not yet approved, and thus no revenue yet. Key competitors once approved include companies with other NASH Cirrhosis drugs. These include companies developing FXR agonists, PPAR agonists, and other antifibrotic agents.
Market Dynamics
Industry Overview
The industry focuses on developing treatments for chronic liver diseases, particularly NASH (nonalcoholic steatohepatitis) and liver cirrhosis. The market is driven by the increasing prevalence of obesity and diabetes, which are major risk factors for NASH.
Positioning
Galectin Therapeutics is positioned as a developer of galectin-3 inhibitors for fibrotic diseases, particularly NASH cirrhosis. They have a specific therapeutic approach targeting galectin-3. Their competitive advantage lies in this specific approach.
Total Addressable Market (TAM)
The NASH market is expected to reach billions of dollars. Galectin Therapeutics' positioning is to capture a segment of the NASH market with their galectin-3 inhibitor, targeting fibrosis.
Upturn SWOT Analysis
Strengths
- Specific therapeutic target (Galectin-3)
- Clinical trial progress
- Experienced management team
Weaknesses
- Single-asset focus (Belapectin)
- High clinical trial risk
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other fibrotic diseases
Threats
- Clinical trial failure
- Competition from other NASH therapies
- Regulatory hurdles
- Funding risks
Competitors and Market Share
Key Competitors
- GILD
- ICPT
- NVS
- MRK
Competitive Landscape
Galectin Therapeutics faces competition from established pharmaceutical companies developing NASH therapies. Their advantage lies in the galectin-3 inhibition mechanism, but they need to demonstrate efficacy and safety in clinical trials to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historically, the company's growth is reflected in its clinical trial progress and development milestones.
Future Projections: Future growth depends on Belapectin's clinical trial success and potential regulatory approvals. Analyst estimates are dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials, partnering efforts, and presentations at medical conferences.
Summary
Galectin Therapeutics is a clinical-stage biotechnology company focused on developing Belapectin for NASH cirrhosis. Success is heavily dependent on positive clinical trial outcomes. The company faces significant competition and requires substantial funding. The company needs to be proactive to keep a steady cash flow for operations and reduce the risk of clinical trial failure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galectin Therapeutics Inc
Exchange NASDAQ | Headquaters Norcross, GA, United States | ||
IPO Launch date 2002-09-09 | President, CEO & Director Mr. Joel Lewis CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://galectintherapeutics.com |
Full time employees 15 | Website https://galectintherapeutics.com | ||
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.